{
  "paper_id": "PMC5801230",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801230/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Fig. 1.",
      "caption": "Cumulative incidence of renal and eye complications over 50 years. Dashed lines show the cumulative incidence of ocular complications, while solid lines show the cumulative incidence of renal complications. BDR Background diabetic retinopathy, ESRD end-stage renal disease, GRP gross proteinuria, MA microalbuminuria, ME macular edema, PDR proliferative diabetic retinopathy, SVL severe vision loss",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/d3276b7f5804/13300_2017_344_Fig1_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/d3276b7f5804/13300_2017_344_Fig1_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/d3276b7f5804/13300_2017_344_Fig1_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/d3276b7f5804/13300_2017_344_Fig1_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/d3276b7f5804/13300_2017_344_Fig1_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC5801230/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/d3276b7f5804/13300_2017_344_Fig1_HTML.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Fig. 3.",
      "caption": "Improvements in quality-adjusted life expectancy with decreasing HbA1c from 7.9% to 7.1% by baseline age",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/1adcb380f4b9/13300_2017_344_Fig3_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/1adcb380f4b9/13300_2017_344_Fig3_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/1adcb380f4b9/13300_2017_344_Fig3_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/1adcb380f4b9/13300_2017_344_Fig3_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/1adcb380f4b9/13300_2017_344_Fig3_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC5801230/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/1adcb380f4b9/13300_2017_344_Fig3_HTML.jpg"
    },
    "figure_4": {
      "figure_number": "Figure 4",
      "title": "Fig. 4.",
      "caption": "Changes in quality-adjusted life expectancy with decreasing HbA1c relative to no change in HbA1c from baseline",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/42499a76db99/13300_2017_344_Fig4_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/42499a76db99/13300_2017_344_Fig4_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/42499a76db99/13300_2017_344_Fig4_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/42499a76db99/13300_2017_344_Fig4_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig4",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/42499a76db99/13300_2017_344_Fig4_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC5801230/images/figure_4.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2f2/5801230/42499a76db99/13300_2017_344_Fig4_HTML.jpg"
    }
  },
  "claims": [
    {
      "sentence": "The cumulative incidence of eye complications and renal complications (Fig. 1) reduced linearly with HbA1c.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "This compared to more modest absolute reductions in congestive heart failure and stroke of 0.45% for both complications with a 0.8% (8.8 mmol/mol) HbA1c reduction (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Improvements in quality-adjusted life expectancy were much more pronounced in younger patients owing in part to the higher baseline life expectancy (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Relatedly, holding HbA1c constant for 10 years, 20 years, and the full model time horizon showed diminishing improvements in quality-adjusted life expectancy (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nChanges in quality-adjusted life expectancy with decreasing HbA1c relative to no change in HbA1c from baselineAs complication incidence was lower with lower HbA1c, costs of diabetes complications also decreased from SEK 761,000 in the reference cohort to SEK 669,000 in the − 0.8% cohort (Fig. 5), a reduction of SEK 92,000.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The cumulative incidence of eye complications and renal complications (Fig. 1) reduced linearly with HbA1c.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "This compared to more modest absolute reductions in congestive heart failure and stroke of 0.45% for both complications with a 0.8% (8.8 mmol/mol) HbA1c reduction (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Improvements in quality-adjusted life expectancy were much more pronounced in younger patients owing in part to the higher baseline life expectancy (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Relatedly, holding HbA1c constant for 10 years, 20 years, and the full model time horizon showed diminishing improvements in quality-adjusted life expectancy (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nChanges in quality-adjusted life expectancy with decreasing HbA1c relative to no change in HbA1c from baselineAs complication incidence was lower with lower HbA1c, costs of diabetes complications also decreased from SEK 761,000 in the reference cohort to SEK 669,000 in the − 0.8% cohort (Fig. 5), a reduction of SEK 92,000.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The cumulative incidence of eye complications and renal complications (Fig. 1) reduced linearly with HbA1c.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "This compared to more modest absolute reductions in congestive heart failure and stroke of 0.45% for both complications with a 0.8% (8.8 mmol/mol) HbA1c reduction (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Improvements in quality-adjusted life expectancy were much more pronounced in younger patients owing in part to the higher baseline life expectancy (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Relatedly, holding HbA1c constant for 10 years, 20 years, and the full model time horizon showed diminishing improvements in quality-adjusted life expectancy (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nChanges in quality-adjusted life expectancy with decreasing HbA1c relative to no change in HbA1c from baselineAs complication incidence was lower with lower HbA1c, costs of diabetes complications also decreased from SEK 761,000 in the reference cohort to SEK 669,000 in the − 0.8% cohort (Fig. 5), a reduction of SEK 92,000.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The cumulative incidence of eye complications and renal complications (Fig. 1) reduced linearly with HbA1c.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "This compared to more modest absolute reductions in congestive heart failure and stroke of 0.45% for both complications with a 0.8% (8.8 mmol/mol) HbA1c reduction (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Improvements in quality-adjusted life expectancy were much more pronounced in younger patients owing in part to the higher baseline life expectancy (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Relatedly, holding HbA1c constant for 10 years, 20 years, and the full model time horizon showed diminishing improvements in quality-adjusted life expectancy (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nChanges in quality-adjusted life expectancy with decreasing HbA1c relative to no change in HbA1c from baselineAs complication incidence was lower with lower HbA1c, costs of diabetes complications also decreased from SEK 761,000 in the reference cohort to SEK 669,000 in the − 0.8% cohort (Fig. 5), a reduction of SEK 92,000.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The cumulative incidence of eye complications and renal complications (Fig. 1) reduced linearly with HbA1c.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "This compared to more modest absolute reductions in congestive heart failure and stroke of 0.45% for both complications with a 0.8% (8.8 mmol/mol) HbA1c reduction (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Improvements in quality-adjusted life expectancy were much more pronounced in younger patients owing in part to the higher baseline life expectancy (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Relatedly, holding HbA1c constant for 10 years, 20 years, and the full model time horizon showed diminishing improvements in quality-adjusted life expectancy (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nChanges in quality-adjusted life expectancy with decreasing HbA1c relative to no change in HbA1c from baselineAs complication incidence was lower with lower HbA1c, costs of diabetes complications also decreased from SEK 761,000 in the reference cohort to SEK 669,000 in the − 0.8% cohort (Fig. 5), a reduction of SEK 92,000.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The cumulative incidence of eye complications and renal complications (Fig. 1) reduced linearly with HbA1c.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "This compared to more modest absolute reductions in congestive heart failure and stroke of 0.45% for both complications with a 0.8% (8.8 mmol/mol) HbA1c reduction (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Improvements in quality-adjusted life expectancy were much more pronounced in younger patients owing in part to the higher baseline life expectancy (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Relatedly, holding HbA1c constant for 10 years, 20 years, and the full model time horizon showed diminishing improvements in quality-adjusted life expectancy (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nChanges in quality-adjusted life expectancy with decreasing HbA1c relative to no change in HbA1c from baselineAs complication incidence was lower with lower HbA1c, costs of diabetes complications also decreased from SEK 761,000 in the reference cohort to SEK 669,000 in the − 0.8% cohort (Fig. 5), a reduction of SEK 92,000.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The cumulative incidence of eye complications and renal complications (Fig. 1) reduced linearly with HbA1c.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "This compared to more modest absolute reductions in congestive heart failure and stroke of 0.45% for both complications with a 0.8% (8.8 mmol/mol) HbA1c reduction (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Improvements in quality-adjusted life expectancy were much more pronounced in younger patients owing in part to the higher baseline life expectancy (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Relatedly, holding HbA1c constant for 10 years, 20 years, and the full model time horizon showed diminishing improvements in quality-adjusted life expectancy (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nChanges in quality-adjusted life expectancy with decreasing HbA1c relative to no change in HbA1c from baselineAs complication incidence was lower with lower HbA1c, costs of diabetes complications also decreased from SEK 761,000 in the reference cohort to SEK 669,000 in the − 0.8% cohort (Fig. 5), a reduction of SEK 92,000.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The cumulative incidence of eye complications and renal complications (Fig. 1) reduced linearly with HbA1c.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "This compared to more modest absolute reductions in congestive heart failure and stroke of 0.45% for both complications with a 0.8% (8.8 mmol/mol) HbA1c reduction (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Improvements in quality-adjusted life expectancy were much more pronounced in younger patients owing in part to the higher baseline life expectancy (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Relatedly, holding HbA1c constant for 10 years, 20 years, and the full model time horizon showed diminishing improvements in quality-adjusted life expectancy (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nChanges in quality-adjusted life expectancy with decreasing HbA1c relative to no change in HbA1c from baselineAs complication incidence was lower with lower HbA1c, costs of diabetes complications also decreased from SEK 761,000 in the reference cohort to SEK 669,000 in the − 0.8% cohort (Fig. 5), a reduction of SEK 92,000.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The cumulative incidence of eye complications and renal complications (Fig. 1) reduced linearly with HbA1c.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "This compared to more modest absolute reductions in congestive heart failure and stroke of 0.45% for both complications with a 0.8% (8.8 mmol/mol) HbA1c reduction (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Improvements in quality-adjusted life expectancy were much more pronounced in younger patients owing in part to the higher baseline life expectancy (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Relatedly, holding HbA1c constant for 10 years, 20 years, and the full model time horizon showed diminishing improvements in quality-adjusted life expectancy (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nChanges in quality-adjusted life expectancy with decreasing HbA1c relative to no change in HbA1c from baselineAs complication incidence was lower with lower HbA1c, costs of diabetes complications also decreased from SEK 761,000 in the reference cohort to SEK 669,000 in the − 0.8% cohort (Fig. 5), a reduction of SEK 92,000.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The cumulative incidence of eye complications and renal complications (Fig. 1) reduced linearly with HbA1c.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "This compared to more modest absolute reductions in congestive heart failure and stroke of 0.45% for both complications with a 0.8% (8.8 mmol/mol) HbA1c reduction (Fig. 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Improvements in quality-adjusted life expectancy were much more pronounced in younger patients owing in part to the higher baseline life expectancy (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Relatedly, holding HbA1c constant for 10 years, 20 years, and the full model time horizon showed diminishing improvements in quality-adjusted life expectancy (Fig. 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "As complication incidence was lower with lower HbA1c, costs of diabetes complications also decreased from SEK 761,000 in the reference cohort to SEK 669,000 in the − 0.8% cohort (Fig. 5), a reduction of SEK 92,000.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 3,
    "claims_count": 50,
    "images_downloaded": 3,
    "tables_filtered": 124
  }
}